PTSD en stress disorder
Conditions
Interventions
Patients participating in this study, will be randomly allocated to one of two
interventions: either paroxetine or TF-CBT.
Paroxetine treatment will have a duration of 24 weeks. The dosage will sta
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: CAPS score of * 50 Male and female, aged 18 years and above Written informed consent Eligible for exposure therapy
Exclusion criteria
Exclusion criteria: Suicidal risk Presence of a psychotic disorder, a bipolar disorder, depression with psychotic features, or excessive substance related disorder over the past 6 months. Primary diagnosis of severe depressive disorder An organic disorder Intolerance to paroxetine or any other SSRI, taking psychotropic medications Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in PTSD symptoms before and after treatment (at week 1, 3, 6 months, 12 and 18 months after treatment), measured by the CAPS and determination of the cost-effectiveness. The primary cost-effectiveness analysis will be one that evaluates costs associated with an improved PTSD outcome in terms of CAPS scores. | — |
Secondary
| Measure | Time frame |
|---|---|
| At 1 week, and 3, 6, 12 and 18 months post-intervention the following secondary outcomes will be assessed as well: response rate (criteria for response are a 30% or more change compared to baseline on CAPS and a CGI score from 1 or two ("much improved" or "very much improved"), possible other psychopathology, quality of life, anxiety and depression and costs, as well as neuroendocrine and neuro-immune measures, neurocognitive functioning and genetic measures. | — |
Countries
Netherlands
Outcome results
None listed